INFO & CONTACTS:  +39 02 2390 1
Dr. Licitra

Associate Professor Licitra Lisa Francesca Linda

Doctor

Contacts
  • Mail: amo@istitutotumori.mi.it
  • Tel: 02 23902150 (dalle 09:00 alle 10:00, dal lunedì al venerdì)
  • Tel: 02 2390 1 (CUP)
Specialty / Department
  • Medical Oncology

Specialized in Medical Oncology, with experience in the treatment of head and neck tumors. She is Associate Professor at the University of Milan (November 2016-to present), where she teaches Oncology in the Faculty of Medicine and in Master's programs in Biotechnology, Psycho-Oncology, Pharmacology, International Medical School, and the ENT specialty. 

She is Chair of the Medical Oncology 3 Unit – Head and Neck Tumors at the Fondazione IRCCS National Cancer Institute, Milan, Italy. 

She is the Scientific Director of the National Center for Oncological Hadrontherapy (CNAO) (2019-to present). 

She was Vice President of the EORTC (European Organisation for Research and Treatment of Cancer) from 2018 to 2021. She is co-founder and member of the European Head and Neck Cancer Society, a member of the Clinical Editorial Board of Oral Oncology and of the UICC TNM Staging Committee. She is an Honorary Member of ESTRO (European Society of Radiation Oncology) and leads the G7 domain within EURACAN (European Network for Rare Adult Solid Cancer). 

She was awarded the AIRC/FIRC Venosta Prize and received the ESMO Award in 2021 for her work in advancing medical oncology. 

Since March 2024, she has been the Scientific Coordinator of ACC (Alleanza Contro il Cancro). 

She is the author of 411 peer-reviewed journal articles and has an H-index of 75 (Scopus). 

Medical Oncology 3 – Head and Neck Cancers

A multicenter, randomized, double-blind, Phase II/III study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab as first-line treatment in patients with recurrent or metastatic PD-L1–positive head an

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of AV-299 in Combination with Cetuximab in Participants with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma

A Phase 2/3, Randomized Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First-Line Treatment for Patients With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Expressing

A Phase 3 Open-Label Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, In Comparison with Standard of Care Platinum/Pembrolizumab/5-FU, in Participants with Recurrent/Metastatic Head and Neck Squamous Ce

A Phase III, Randomized, Open-Label, Multi-Center, Global Study of MEDI5752 as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Pr

Phase II randomized study of Fianlimab plus Cemiplimab versus Cemiplimab plus placebo in first-line treatment of participants with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) that is posit

Big Data Models and Intelligent tools for Quality of Life monitoring and participatory empowerment of head and neck cancer survivors (BD4QoL)

Matching primary tumor and blood gene expression analysis of HPV-negative squamous head and neck cancers (BIOMATCH - Head and Neck) - PNRR-MCNT1-2023-12377359

Optimizing biomarkers of immunotherapy response in clinical studies summarizing head and neck cancer natural history

Last update: 14/10/2025

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe